Your browser doesn't support javascript.
loading
Can pharmaceutical care decrease the oxidative stress in type 2 diabetes mellitus?
Lira-Meriguete, Angélica Marchesi; Santos, Mayara Paes; Viana, Vivian Cerqueira de Souza; Gonçalves, Nadmy Arrivabene Zavaris; Kitagawa, Rodrigo Rezende; Carnielli-Queiroz, Lorena; Bem, Daniela Amorim Melgaço Guimarães do; Gonçalves, Rita de Cássia Ribeiro.
Afiliación
  • Lira-Meriguete AM; Graduate Program in Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil.
  • Santos MP; Graduate Program in Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil.
  • Viana VCS; Municipal Secretary of Health of the City of Vitória, Espírito Santo, Brazil.
  • Gonçalves NAZ; Municipal Secretary of Health of the City of Vitória, Espírito Santo, Brazil.
  • Kitagawa RR; Graduate Program in Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil; Department of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil.
  • Carnielli-Queiroz L; Department of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil.
  • Bem DAMGD; Graduate Program in Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil; Department of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil.
  • Gonçalves RCR; Graduate Program in Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil; Department of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Brazil. Electronic address: rita.goncalves@ufes.br.
Biomed Pharmacother ; 171: 116178, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38266624
ABSTRACT
Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder characterized by an increase in oxidative stress, which is itself related to development of T2D's main chronic complications. Oxidative stress caused by elevated production of reactive species of oxygen and decrease of antioxidant defense system level, leads to activation of lipid peroxidation (LPO) and oxidative lipoprotein modification with increasing atherogenicity. Therefore, the aim of this study was to evaluate whether pharmacotherapeutic follow-up in patients with T2D, users and non-users of insulin, interferes with the levels of oxidative stress, measuring lipid peroxidation and protein oxidation, nitric oxide and superoxide dismutase levels. After the follow-up, there was a decrease in nitric oxide levels and an increase in superoxide dismutase concentration for the group with insulin therapy. Accordingly, these results show that the proposed pharmaceutical care program reduced the oxidative stress levels, mainly in patients in insulin therapy, as a consequence, can impact in the surging of the main chronic complications in T2D.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Francia